The Fools at Motley Fail to understand..

..the importance of the May 30th American Society of Clinical Oncology (ASCO) conference as a driver for Genentech (DNA). http://www.asco.org/ASCO/Meetings/ASCO+Annual+Meeting POTC predicted the failure of Rituxan for Lupus after analyzing the CC psychology on April 10th. POTC also was forward-looking in suggesting investors WAIT until after the failed Rituxan studies are disseminated. Although we respect Motley Fool's opinions from time to time, we feel their story today is poor. It misleads investors in to thinking Rituxan was supposed to succeed. Also, Rituxan cannot be compared to Avastin in terms of future revenue and profit streams. Our readers would be wise to ignore the recent Motley Fool story and look-forward to the ground breaking news we see DNA presenting surrounding their block buster cancer drug Avastin's extended uses at ASCO on May 30th. POTC reiterates DNA is the leader in the biotechnology universe of stocks and we hope you do not become distracted by backward looking articles: http://msn.fool.com/investing/high-growth/2008/04/30/a-tale-of-two-dna-drugs.aspx?logvisit=y&source=eedmsnlnk0010001&published=2008-04-30 Thank You for your attention, The Psychology of the Call team.